Transient Hypothyroxinemia of Prematurity is Associated with Abnormal Cranial Ultrasound and Illness Severity

ABSTRACT

Transient hypothyroxinemia without elevated thyroid-stimulating hormone (TSH) levels is common in prematurity, especially in very-low-birth-weight (VLBW) infants. The transient hypothyroxinemia of prematurity (THOP) has been seen as a ``benign'' condition not requiring medical treatment. However, some recent large observational studies have revealed a relationship between THOP and abnormal neurodevelopment. Furthermore, one study showed THOP had twice the risk of brain echolucency, which was the best predictable neurodevelopmental dysfunction, than the premature infants with normal or higher thyroxine levels. The relationships among THOP, illness severity, and neurodevelopmental dysfunction remain unclear. We propose a hypothesis that THOP is associated with abnormal ultrasound and illness severity. We studied 54 infants who were admitted more than 14 days at our neonatal intensive care unit (NICU) with a birth weight <2000 g from March 1999 to March 2000. The infants received serum thyroxine (T4), free-T4, and TSH measurement during the first weeks of life. Most of them had serum thyroxine levels measured at approximately 2 weeks of age. The infants enrolled in the study were examined by at least 1 of 3 cranial ultrasounds during the first weeks of life, illness severity evaluation according to the neonatal therapeutic intervention scoring system (NTISS) score, as well as NICU hospital stay period. Infant were classified as THOP by T4 value <5.3 μg/dL (68 nmol/L), which is 2.6 SD below the mean for term infants in Massachusetts, without elevated TSH value (<20 μIU/mL). After adjusting for some confounding factors, such as gestational age, birth weight, duration of mechanical ventilation, infants with THOP were associated with abnormal cranial ultrasound, illness severity, and lower 1-minute Apgar score. In our studies, THOP was related with brain ultrasound anomaly, neonatal illness, and lower Apgar score at 1 minute. Does early thyroxine intervention improve the prognosis and neurodevelopmental dysfunction? This question requires further investigation.

Preterm - hypothyroxinemia - brain echolucency - thyroxine - NTISS - illness severity

REFERENCES

• 1 Baas D, Bourbeau D, Sarlieve L L. Oligodendrocyte maturation and progenitor cell proliferation are independently regulated by thyroid hormone.  Glia . 1997;  19 324-332
• 2 Lucas A, Rennie J, Baker B A. Low plasma triiodothyronine concentrations and outcome in preterm infants.  Arch Dis Child . 1988;  63 1201-1206
• 3 Meijer W J, Verloove-Vanhorick S P, Brand R. Transient hypothyroxinemia associated with developmental delay in very preterm infants.  Arch Dis Child . 1992;  67 944-947
• 4 Reuss M L, Paneth N, Lorenz J L. The relation of transient hypothyroxinemia in preterm infants to neurodevelopment at two years of age.  N Engl J Med . 1996;  334 821-827
• 5 Leviton A, Paneth N, Reuss M L. Hypothyroxinemia of prematurity and the risk of cerebral white matter damage.  J Pediatr . 1999;  134 706-711
• 6 Klein R Z, Carlton E L, Faix J D. Thyroid function in very low birth weight infants.  Clin Endocrinol . 1997;  47 411-417
• 7 Fisher D A, Klein A H. Thyroid development and disorders of thyroid function in the newborn.  N Engl J Med . 1981;  304 702-712
• 8 Hadeed A J, Asay L D, Klein A H, Fisher D A. Significance of transient hypothyroxinemia in premature infants with and without respiratory distress syndrome.  Pediatrics . 1981;  68 494-498
• 9 Brock-Jacobsen B, Peitersen B, Andersen H J. Serum concentrations of thyroxine-binding globulin, prealbumin and albumin in healthy fullterm, small-for-gestational-age and preterm newborn infants.  Acta Paediatr Scand . 1979;  68 49-55
• 10 Brock-Jacobsen B, Hummer L. Changes in serum concentrations of thyroid hormones and thyroid hormone-binding proteins during early infancy.  Acta Paediatr Scand . 1979;  68 411-418
• 11 Greenberg A H, Czernichow P, Reba R C, Tyson J, Blizzard R M. Observations on the maturation of thyroid function in early fetal life.  J Clin Invest . 1970;  49 1790-1803
• 12 Mitchell M L, Walraven C, Rojas D A. Screening very-low-birth weight infants for congenital hypothyroidism.  Lancet . 1994;  343 60-61
• 13 Frank J E, Faix J E, Hermos R J. Thyroid function in very low birth weight infants: effects on neonatal hypothyroidism screening.  J Pediatr . 1996;  128 548-554
• 14 Adams L M, Emery J R, Clark S J. Reference ranges for newer thyroid function tests in premature infants.  J Pediatr . 1995;  126 122-127
• 15 Polk D H, Fisher D A. Disorders of the thyroid gland. In: Taeusch HW, Ballard RA, Avery ME, eds. Disease of the Newborn Philadelphia: WB Saunders 1998: 1224-1234
• 16 van Wassenaer G A, Kok J H, De Vijlder J M J. Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation.  N Engl J Med . 1997;  336 21-26
• 17 Fisher D A. Hypothyroxinemia in premature infants: is thyroxine treatment necessary?.  Thyroid . 1999;  9 715-720
• 18 ACTOBAT Study Group. Australian collaborative trial of antenatal thyrotropin releasing hormone (ACTOBAT) for the prevention of neonatal respiratory disease.  Lancet . 1995;  345 877-882
• 19 Ballard R A, Ballard P L, Creasy R K. Respiratory distress in very-low-birth weight infants after prenatal thyrotropin-releasing hormone and glucocorticoid.  Lancet . 1992;  339 510-515
• 20 Knight D B, Liggins G C, Wealthall S R. A randomized, controlled trial of antepartum thyrotropin-releasing hormone and betamethasone in the prevention of respiratory disease in preterm infants.  Am J Obstet Gynecol . 1994;  171 11-16
• 21 Morales W J, O'Brien W F, Angel J L. Fetal lung maturation: the combined use of corticosteroids and thyrotropin-releasing hormone.  Obstet Gynecol . 1989;  73 111-116